Prosight Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Prosight Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-450,000	Closed	-$1.81M	–	51
2019 Q4	$1.81M	Buy	+450,000	New	+$1.56M	0.8%	31
2018 Q3	–	Sell	-144,752	Closed	-$1.48M	–	37
2018 Q2	$1.48M	Sell	144,752 -3,930	-3%	-$44.5K	1.08%	22
2018 Q1	$1.93M	Sell	148,682 -29,771	-17%	-$443K	1.21%	25
2017 Q4	$3.19M	Buy	+178,453	New	+$3.72M	2.35%	17

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prosight Management's PRTK Position: Q1 2020 in Review

Prosight Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 450,000 shares — an estimated $1.81M sold.

Prosight Management first reported a position in PRTK in Q4 2017 and held it in 4 quarters. The position peaked at $3.19M in Q4 2017. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

Prosight Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Prosight Management sold 450,000 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.81M.
Prosight Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Prosight Management's Paratek Pharmaceuticals, Inc. position peaked at $3.19M in Q4 2017.
85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Prosight Management's 13F filing for Q1 2020, filed 15 May 2020.